CoChat

The safety of subcutaneously administered depot medroxyprogesterone acetate (104 mg/0.65 mL): A systematic review

Open access
Dragoman, Monica V., Gaffield, Mary E. · 2016 · Contraception
Cited by 52

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

CONTEXT: Depot medroxyprogesterone acetate (DMPA), a progestogen-only contraceptive injectable, has traditionally been formulated as a crystalline suspension delivered intramuscularly (IM) at a dose of 150mg/1.0mL. A new, lower dose formulation of DMPA (104mg/0.65mL) has been developed for subcutaneous administration (SC). Given its increasing global availability and public health relevance, DMPA-SC was prioritized for inclusion as a new method referenced in the World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use (MEC), 5th Edition. OBJECTIVE: This systematic review evaluated the published peer-reviewed literature regarding the safety of DMPA-SC among women with various characteristics or medical conditions. Results of this review informed the decision-making of a WHO Guideline Development Group in order to include recommendations on contraceptive eligibility within the revised MEC. METHODS: We searched PubMed and Cochrane Library databases to identify all relevant evidence published in peer-reviewed journals regarding the safety of DMPA-SC when used by women of reproductive age, particularly those with select characteristics or conditions specified in the MEC, from inception through June 2015. The quality of each individual study was assessed using the system for grading evidence developed by the United States Preventive Services Task Force. RESULTS: Fourteen studies met criteria for inclusion. Ten reported results relevant to DMPA users of varying age or with obesity, endometriosis or HIV; four compared the safety of DMPA-SC and DMPA-IM when used by general populations of healthy women. A randomized trial evaluating changes in bone mineral density among adult DMPA-SC and DMPA-IM users demonstrated no differences at 2years of follow-up. Limited evidence reported no consistent differences in weight change or bleeding patterns according to age; however, adolescents (<18years) were not included in any studies. Similar contraceptive efficacy, weight change, bleeding patterns and occurrence of other adverse effects among obese and nonobese DMPA-SC users were observed. Women with endometriosis using DMPA-SC over 6months had minimal decreases in bone mineral density, weight gain, few serious adverse events and experienced improved pain symptoms. Women living with HIV tolerated injection of DMPA-SC with rare complications. DMPA-SC and DMPA-IM also show therapeutic equivalence and similar effects on weight gain, changes in bleeding patterns and reports of other adverse effects when these different delivery systems were used by general populations of women. CONCLUSION: Evidence for use of DMPA-SC by women with select conditions and characteristics including age, obesity, endometriosis or HIV demonstrates that this method can generally be used safely in these contexts. Further, DMPA-SC and DMPA-IM appear to be therapeutically equivalent with similar safety profiles when used by healthy women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.contraception.2016.02.003

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 21

  1. Draper, 2006, Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception, Cochrane Database Syst Rev, 3, CD005214
  2. Westhoff, 2003, Depot-medroxyprogesterone acetate injection (Depo-Provera®): a highly effective contraceptive option with proven long-term safety, Contraception, 68, 75, 10.1016/S0010-7824(03)00136-7 · DOI
  3. Jain, 2004, Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera, Contraception, 70, 11, 10.1016/j.contraception.2004.01.011 · DOI
  4. Halpern, 2014, Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm, Contraception, 89, 31, 10.1016/j.contraception.2013.07.002 · DOI
  5. Jain, 2004, Contraceptive efficacy and safety of DMPA-SC, Contraception, 70, 269, 10.1016/j.contraception.2004.06.011 · DOI · Paper page
  6. Mohllajee, 2005, Keeping up with evidence a new system for WHO's evidence-based family planning guidance, Am J Prev Med, 28, 483, 10.1016/j.amepre.2005.02.008 · DOI
  7. Harris, 2001, Current methods of the US preventive services task force: a review of the process, Am J Prev Med, 20S, 21, 10.1016/S0749-3797(01)00261-6 · DOI · Paper page
  8. Arias, 2006, Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104mg, Contraception, 74, 234, 10.1016/j.contraception.2006.03.008 · DOI
  9. Westhoff, 2007, Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104mg/0.65mL, Contraception, 75, 261, 10.1016/j.contraception.2006.12.009 · DOI
  10. Segall-Gutierrez, 2010, Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously, Contraception, 81, 487, 10.1016/j.contraception.2010.01.021 · DOI
  11. Segall-Gutierrez, 2012, Effect of subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women, Contraception, 86, 739, 10.1016/j.contraception.2012.05.148 · DOI
  12. Segall-Gutierrez, 2012, Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use, Contraception, 85, 36, 10.1016/j.contraception.2011.04.016 · DOI
  13. Segall-Gutierrez, 2013, A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate, Eur J Contracept Reprod Health Care, 18, 199, 10.3109/13625187.2013.774358 · DOI
  14. Polis, 2014, Preference for Sayana(R) Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial, Contraception, 89, 385, 10.1016/j.contraception.2013.11.008 · DOI
  15. Goldstein, 2007, Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study, Fertil Steril, 87, 1267, 10.1016/j.fertnstert.2006.11.040 · DOI
  16. Burke, 2014, Observational study of the acceptability of sayana(R) press among intramuscular DMPA users in Uganda and Senegal, Contraception, 89, 361, 10.1016/j.contraception.2014.01.022 · DOI
  17. Lexchin, 2005, Implications of pharmaceutical industry funding on clinical research, Ann Pharmacother, 39, 194, 10.1345/aph.1E224 · DOI
  18. Grimes, 2005, Surrogate end points in clinical research: hazardous to your health, Obstet Gynecol, 105, 1114, 10.1097/01.AOG.0000157445.67309.19 · DOI · Paper page
  19. Williams, 2013, Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women, Contraception, 88, 401, 10.1016/j.contraception.2012.11.019 · doi:10.1016/j.contraception.2012.11.019
  20. Cameron, 2012, Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception, Contraception, 85, 458, 10.1016/j.contraception.2011.10.002 · DOI
  21. Prabhakaran, 2012, Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability, Contraception, 85, 453, 10.1016/j.contraception.2011.09.015 · doi:10.1016/j.contraception.2011.09.015

Cited by

See all 52

Metadata

Authors
Dragoman, M. V., & Gaffield, M. E.
Venue
Contraception
Publisher
Elsevier BV
Published
2016-09
Volume
94
Issue
3
Pages
202-215
ISSN
0010-7824 (ISSN-L)
OpenAlex
W2260878706
Cited by
52
References
4
FWCI
0.90
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The safety of subcutaneously administered depot medroxyprogesterone acetate (104 mg/0.65 mL): A systematic review. https://app.cochat.ai/papers/10.1016/j.contraception.2016.02.003
The paper
Dragoman, M. V., & Gaffield, M. E. (2016). The safety of subcutaneously administered depot medroxyprogesterone acetate (104 mg/0.65 mL): A systematic review. Contraception. https://doi.org/10.1016/j.contraception.2016.02.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.